Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 05 Apr 2023
Faster UK drug approvals by relying on other countries
5 April 2023 - Safety and efficacy must be prioritised ahead of speed. ...
Posted by Michael Wonder on 05 Apr 2023
Are German drug pricing regulations chasing some drug makers away, causing them to withdraw products from the market?
5 April 2023 - Germany’s pharmaceutical market is the most important one on the European continent. ...
Posted by Michael Wonder on 05 Apr 2023
Global blockbusters’ failure to win insurance coverage raises questions about fairness
5 April 2023 - Here is a case in which patients' treatment options and companies' business rights have been put ...
Posted by Michael Wonder on 04 Apr 2023
FDA accepts Pfizer’s supplemental new drug applications for Braftovi + Mektovi
4 April 2023 - Supplemental new drug applications are supported by results from the PHAROS trial, evaluating the combination in ...
Posted by Michael Wonder on 04 Apr 2023
Shionogi receives US FDA fast track designation for ensitrelvir fumaric acid, an investigational oral anti-viral for COVID-19
4 April 2023 - Shionogi today announced that the US FDA has granted fast track designation for their investigational COVID-19 ...
Posted by Michael Wonder on 04 Apr 2023
FDA authorises Gohibic (vilobelimab) injection for the treatment of COVID-19
4 April 2023 - The FDA has issued an emergency use authorisation for the use of Gohibic (vilobelimab) injection for ...
Posted by Michael Wonder on 04 Apr 2023
TLV reconsiders the subsidy of Lumykras (sotorasib)
4 April 2023 - TLV has started a review of Lumykras (sotorasib). Lumykras (sotorasib) has already been included in the high-cost ...
Posted by Michael Wonder on 04 Apr 2023
Long-waited drugs were approved, but patients must wait for insurance benefits
4 April 2023 - Braftovi (encorafenib) is a targeted agent used for VRAF V600E mutant metastatic colorectal cancer patients with ...
Posted by Michael Wonder on 04 Apr 2023
Daridorexant for the treatment of patients with insomnia disorder
3 April 2023 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 04 Apr 2023
New features further strengthen Priority Medicines scheme (PRIME)
4 April 2023 - The EMA is introducing a number of new features to the PRIority Medicines (PRIME) scheme to ...
Posted by Michael Wonder on 04 Apr 2023
Medicare non-compliance and fraud costing Australians
4 April 2023 - The Albanese Government has today released the findings of a review into the compliance system that underpins ...
Posted by Michael Wonder on 04 Apr 2023
PHARMAC seeking feedback on the COVID-19 anti-viral molnupiravir
4 April 2023 - PHARMAC are consulting on the role of molnupiravir in New Zealand’s portfolio of COVID-19 treatments. ...
Posted by Michael Wonder on 04 Apr 2023
Koselugo approved in Canada for paediatric patients with neurofibromatosis type 1 plexiform neurofibromas
3 April 2023 - First and only therapy approved to treat this rare and debilitating genetic condition. ...
Posted by Michael Wonder on 04 Apr 2023
HUTCHMED completes rolling submission of NDA to US FDA for fruquintinib for the treatment of refractory metastatic colorectal cancer
31 March 2023 - NDA supported by data from global Phase 3 FRESCO-2 study in the US, Europe, Japan and Australia ...
Posted by Michael Wonder on 04 Apr 2023
Chiesi Global Rare Diseases announces approval of Ferriprox MR deferiprone extended release tablets in Canada
31 March 2023 - New formulation allows twice-daily dosing in patients with transfusional iron overload due to thalassaemia syndromes when ...